Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease. Issue 7 (2nd September 2014)

• Record Type: Journal Article
• Authors: O'Connor, Eibhlís M.; Grealy, Geraldine; McCarthy, Jane; Desmond, Alan; Craig, Orla; Shanahan, Fergus; Cashman, Kevin D.
• Is Part Of: British journal of nutrition. Volume 112:Issue 7(2014)
• Page Start: 1163
• Page End: 1174
• Publication Date: 2014-09-02
• Subjects: Phylloquinone (vitamin K1), -- Percentage of undercarboxylated osteocalcin, -- Bone health indices, -- Intervention studies, -- Crohn's disease; Nutrition -- Periodicals; 572.4
• DOI: 10.1017/S0007114514001913
• Languages: English
• ISSNs: 0007-1145

Abstract

Abstract : Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn's disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K1 ). By conducting two RCT, the present study aimed to first establish whether supplementation with 1000 μg of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD ( n 10 per group) using 0 (placebo), 1000 or 2000 μg of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v . 1000 μg vitamin K/d (both co-administered with Ca (500 mg/d) and vitamin D3 (10 μg/d)) for 12 months ( n 43 per group) on the biochemical indices of bone turnover (determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline, the mean %ucOC was 47 %, and this was suppressed upon supplementation with 1000 μg of phylloquinone daily ( − 81 %; P < 0·01) and not suppressed further by 2000 μg of phylloquinone daily. Compared with the placebo, supplementation with 1000 μg of phylloquinone daily for 12 months had no significant effect ( P >0·1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but modestly increased ( P < 0·05) the bone mass of the total radius. Despite near maximal suppression of serum %ucOC, supplementation with 1000 μg of phylloquinone daily (with Ca and vitamin D3 ) had no effect on the indices of bone health in adult CD patients with likely vitamin K insufficiency.